There are currently 168 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Autism participants are Ohio, California, Illinois and Michigan.
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342
Recruiting
This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer. How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to us... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Register for Updates
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT00001823
Recruiting
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT01931644
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Register for Updates
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: City of Hope National Medical Center, Duarte, California +9 locations
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma
Register for Updates
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
NCT04017819
Recruiting
Primary Objectives Determine the biodistribution of [18F]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives Determine the dosimetry of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. Determine the acute toxicity of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. Determine whether uptake in [18F]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Stanford University, Stanford, California
Conditions: Cancer, Lung Cancer
Register for Updates
Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning
NCT04105283
Recruiting
This research study will evaluate the administration of a particle called macro-aggregated albumin (MAA) labelled with the radiotracer technetium 99m (Tc99m) as a proxy to estimate the anticipated dose of radiation to tumor and adjacent structures. Administration of this labeled MAA will not have a therapeutic benefit on the participant's cancer. Administration will help researchers determine if arterial administration of radiation may be feasible for lung cancer in the future.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Lung Cancer
Register for Updates
Adaptive Symptom Self-Management Immunotherapy Study
NCT05715255
Recruiting
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona +1 locations
Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Register for Updates
Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung
NCT04060927
Recruiting
This is a pilot study designed to to provide data and experience comparing two different techniques of breath hold SBRT treatments. The first technique will include SGRT, but with the assistance of implanted fiducials. Subjects will be treated with a breath hold technique utilizing SGRT, but will also be imaged during treatment with fiducial match. The second technique will utilize SGRT for breath hold treatments without the assistance of implanted fiducials/continuous imaging.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Lung Cancer
Register for Updates
Empathic Communication Skills (ECS) Training
NCT05456841
Recruiting
Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA2... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/11/2024
Locations: Providence St. Joseph Health (Data Collection Only), Irvine, California +6 locations
Conditions: Lung Cancer
Register for Updates
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548
Recruiting
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey +10 locations
Conditions: Head and Neck Cancer, Lung Cancer
Register for Updates
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613
Recruiting
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Orlando Health Cancer Institute (Melanoma), Orlando, Florida +3 locations
Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Register for Updates
Increasing Equity in Lung Cancer Screening
NCT06360822
Recruiting
The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/08/2024
Locations: Eskenazi Health, Indianapolis, Indiana
Conditions: Lung Cancer
Register for Updates